The objective of this study was to investigate the correlation between in vitro and in vivo liposome-complement interactions. Third component of the complement (C3) fragments associated with hydrogenated egg phosphatidylcholine (HEPC)-based liposomes in vivo and complement-dependent destabilization in vitro were determined as an indication of liposome-complement interaction in vivo and in vitro, respectively. C3 fragments on the liposomes were detected in both rats and guinea pigs. Pretreatment with K76COOH (K76), a complement inactivating agent, reduced the binding of C3 fragments. These findings indicated that the liposomes remarkably activated the complement system in both animals in vivo. Interestingly, significant complement-dependent liposome destabilization was observed in rat serum, but not in guinea pig serum, indicating that the liposomes activated the complement system in rats, but not in guinea pigs in vitro. Taken together, it is apparent that in vitro complement activation by the liposomes is not in agreement with in vivo complement activation in ginea pigs. This discrepancy in the liposome-complement interaction would suggest the need for further investigation to utilize the information obtained from the liposome-complement interaction to predict in vivo behavior of the liposomes.
Accumulation of liposomes in the mononuclear phagocyte system (MPS) and destabilization of liposomes in blood are important factors which affect liposome circulation times. We and many researchers have reported that the liposomecomplement interaction contributes to the destabilization of liposomes in blood and the uptake of liposomes by the cells of the MPS, resulting in rapid clearance of liposomes from blood.
3-7) Therefore, we have hypothesized that evaluation of the liposome-complement interaction quantitatively in vivo would be useful to understand and predict the behavior of liposomes following administration into the body in the use of liposomes as drug carriers.
However, as far as we know, there is no report showing quantitative determination of in vivo liposome-complement interaction. In this study, therefore, we tried to determine the in vivo liposome-complement interaction, and then investigate if there is good correlation in in vivo and in vitro liposome-complement interaction. The amount of third component of the complement (C3) fragments associated with hydrogenated egg phosphatidylcholine (HEPC)-based liposomes was determined as an indication of the activation of the complement system in vivo, since the C3 fragment is one component of the complement system and is well-known as a major opsonin. 8) Complement-dependent liposome destabilization in both isolated rat and guinea pig serum was also measured in order to evaluate if the amount of C3 fragments associated with the liposomes in vivo reflects the complement-dependent destabilization of the liposomes in vitro.
MATERIALS AND METHODS

Materials and Animals HEPC was donated by Nippon
Fine Chemical (Osaka, Japan). Dicetylphosphate (DCP) was purchased from Nacalai Tesque (Kyoto, Japan). Cholesterol (CHOL) was of analytical grade (Wako Pure Chemical, Osaka, Japan). K76COOH (K76) was a gift from Otsuka Pharmaceutical Co. (Tokushima, Japan). All other reagents were of analytical grade.
Male Hartley guinea pigs (300-400 g) and male Wistar rats (180-230 g) were purchased from Inoue Experimental Animal (Kumamoto, Japan).
Preparation of Liposomes Preparation of multilamellar vesicles (MLV) was performed by modification of a conventional lipid film hydration method earlier described. 9) Liposomes were composed of HEPC/CHOL/DCP at a molar ratio of 5 : 4 : 1 and sized by extrusion through polycarbonate membrane filters (Nuclepore Co., CA, U.S.A.) with pore size of 800 nm. Mean diameters of liposomes (765-835 nm) were determined using a NICOMP 370 HPL submicron particle analyzer (Particle Sizing System, CA, U.S.A.). 5(6)-Carboxyfluorescein ((CF) Eastman Kodak Co., NY, U.S.A.) was encapsulated as an internal space marker to measure liposome destabilization in vitro. For determining C3 fragments associated with liposomes, the liposomes were labeled with a trace amount of 3 H-cholesterylhexadecyl ether ( 3 H-CHE, (NEN Research Products, MA, U.S.A.)) (1 mCi/ 40 mmol of total lipids) as a nonexchangeable lipid phase marker. 8, 9) Determination of C3 Fragments Associated with Isolated Liposomes For in vivo interaction, the liposomes labeled with 3 H-CHE were administered intravenously through the femoral vein cannula into animals. The injected volume was 2.5 ml/kg body weight with a dose corresponding to 12 mmol as total lipid/kg body weight for guinea pigs or 15 mmol as total lipid/kg body weight for rats. To examine the effect of lack of the complement system on the C3 binding, several animals were treated with K76 (100 mg/kg) 12) 1 h before the liposome administration. Two minutes after liposome injection, blood was collected via the carotid artery. The serum was separated from the isolated blood by centrifugation (1000 rpm, 30 min). The liposomes were recovered by using a spin column procedure 14) with a 10 ml BioGel A-15m, 200-400 mesh size (Bio-Rad) spin column. The amount of C3 fragments extracted from isolated liposomes was determined according to the method described previously.
15) The C3 fragments associated with the liposomes were expressed as ng per mmol of liposomal lipid. In Vitro Liposome Destabilization Assay Liposome destabilization in serum was assessed by determining the fluorescence intensity of released CF according to a previously described method. 9) To examine the contribution of the complement system to the liposome destabilization, sera were pretreated with K76 (1.5 mg/ml) 12) and heated at 56°C for 30 min. 13) Percentage of CF released from liposomes was calculated by dividing the fluorescence intensity of the reaction mixture by that of the total encapsulated CF in the liposomes.
Statistics Statistic analyses were performed using StatView software (Abacus Concepts, Inc., CA, U.S.A.).
RESULTS
Determination of C3 Fragments Associated with the HEPC-Based Liposomes in Vivo C3 fragments associated with the liposomes in vivo were determined as an indication of the in vivo liposome-complement interaction. The liposomes were administered intravenously into rats and guinea pigs, and were isolated from blood after 2 min using a spin column procedure.
14) The extracted C3 fragments from the isolated liposomes were determined with a recently developed an enzyme-linked immunosorbent assay (ELISA) assay system. 15) As shown in Fig. 1 , C3 fragments associated with the liposomes were detectable and the amount of bound C3 fragments was significantly decreased by pretreatment with K76 ( pϽ0.05) in both animals. It appeared that the complement system in both animals was activated by the liposomes in vivo.
Release of CF from HEPC-Based Liposomes in Vitro Destabilization of the liposomes in vitro was examined by measuring the release of the contents (CF) from the liposomes in both rat serum and guinea pig serum. To examine contribution of the complement system to the liposome destabilization, sera were pretreated with K76 (1.5 mg/ml) or by heating at 56°C for 30 min. The release of the contents (CF) from the liposomes following incubation in either untreated serum, pretreated sera or phosphate-buffered saline (PBS) is shown in Fig. 2 . In untreated rat serum, significant release of the CF from the liposomes was observed ( pϽ0.001 vs. the release in PBS). In either K76-treated or heated serum (complement-inactivated sera), the significant release was reduced to the level of the release in PBS. It appeared that the liposomes were destabilized through activation of the complement system in rat serum. On the other hand, in guinea pig, significant CF release was not observed in untreated, K76-treated, heated serum and PBS. It appears that the complement system in guinea pig was not activated by the liposomes in vitro.
DISCUSSION
We have previously investigated the contribution of the complement system to the biodistribution of the HEPC-based liposomes, composed of HEPC, CHOL and DCP, with in vitro, in situ and in vivo assays, and indicated that the activation of the complement system by the liposomes resulted in increased elimination rate of the liposomes from blood circulation.
3,7,9,15-25) However, as far as we know, there was little direct result to show that the liposomes activates the complement system in vivo. In this study, therefore, we tried to determine the complement component deposited on the surface of the liposome following intravenous injection. The C3 fragments, a complement component as well as a critical opsonin, were quantitatively determined as an indication of in vivo liposome-complement interaction. As shown in Fig. 1 , the deposited C3 fragments were successfully detected on the surface of the liposomes collected from the circulation. This obviously indicated that the bindings of C3 fragments resulted from the activation of the complement system by the liposomes, since the bindings were significantly reduced by the pretreatment with a complement inactivating agent, K76, in both animals ( Fig. 1 ). In addition, there was no significant difference in the amount of C3 fragments associated with the liposomes in both animals. This fact provided direct evidence For in vivo interaction, the liposomes (HEPC/CHOL/DCPϭ5 : 4 : 1, mol/mol) were administered intravenously. The injected volume was 2.5 ml/kg body weight with a dose corresponding to 12 mmol as total lipid/kg body weight for guinea pigs or 15 mmol as total lipid/kg body weight for rats. To examine the effect of lack of the complement system on the C3 binding, several animals were treated with K76 (100 mg/kg) 1 h before the liposome administration. Two minutes after liposome injection, the blood was collected. The liposomes were recovered by using a spin column procedure from serum. The amount of C3 fragments extracted from isolated liposomes was determined by using an ELISA procedure. The C3 fragments associated with the liposomes were expressed as ng per mmol of liposomal lipid. Untreated animals (closed column). that the liposomes have ability to activate the complement system in vivo.
Interestingly, complement-dependent destabilization of the liposomes was observed in rat serum, but not in guinea pig serum (Fig. 2) . This indicates that the complement system in rat was activated by the liposomes in vitro, while it was not in guinea pig. In addition, as shown in Figs. 1 and 2 , in guinea pigs, in vivo complement activation by the liposomes was detected, whereas in vitro complement-dependent liposome destabilization did not occur. These discrepancies in the complement activation induced by the liposomes may be due to difference in biological milieu such as a titer of the complement system or difference in the complement activation pathway. In the case of liposome-induced complement activation, in general, the chain reaction can proceed through two basic pathways (classical and alternative). 6) Activation of the classical pathway typically involves the binding of antibodies to the vesicles with subsequent activation of the C1 complex, C2, C4, and C3, leading to the formation of the C3 and C5 convertases. 8) In the case of the alternative pathway activation, formation of C3 convertase is triggered by covalent binding of C3b (an activated fragment of C3) to the membrane. 8) Activation of the terminal sequence (C5b, C6, C7, C8, C9), leading to the formation of a membrane attack complex (MAC), is identical with all liposomes. The CF release is assumed to result from pore formation, namely MAC, on the liposome membrane. The difference in the titer might affect the formation of the MAC on the liposome membrane: lower titer, less release. In addition, difference of the complement activation pathway might affect the degree of the CF release. Devine and co-workers have reported that liposomes composed of egg phosphatidylcholine, CHOL and stearylamine activated the human complement system via the alternative pathway, and liposomes having the same composition activated the rat complement system via the classical pathway. 26, 27) Their report might support our assumption, although experimental evidence could be needed. Further investigation on this point is in progress in our laboratory.
We have recently reported that there is a close relationship between liposome biodistribution and the amount of bound C3 fragments, and we have showed a possibility that quantitative evaluation of the liposome-complement interaction would provide useful information to predict the biodistribution in human. 15) However, the results observed in this study indicate that further careful investigations are necessary to define the usefulness of assessment of the liposome-complement interaction for predicting the biodistribution of liposomes, although the quantitative analysis of the liposomecomplement interaction would give important information for the development of a rational drug delivery system using liposomes as a drug carrier.
